MedicaidPrior AuthMedium impact
Eligard (leuprolide acetate) (Revised)
Humana·OH · Urology, Oncology·Medicaid
Effective date
Jan 1, 2026
We identified it
Jun 24, 2026
Summary
Humana Medicaid Ohio has updated prior authorization requirements for Eligard (leuprolide acetate) subcutaneous injections used to treat advanced prostate cancer. The policy requires members to have advanced prostate cancer or high risk of recurrence and excludes concomitant use with other LHRH analogs.
Action Required
By January 1, 2026: Billing team must ensure prior authorization is obtained for all Eligard (leuprolide acetate) subcutaneous injections for Ohio Medicaid patients. Verify patient has diagnosis of advanced prostate cancer or high risk of disease recurrence and is not using other LHRH analogs concurrently. Claims without proper prior authorization will be denied.